Biogen News and Research

RSS
EHSI to sign definitive agreement with OceanBASIS

EHSI to sign definitive agreement with OceanBASIS

Santarus commences SAN-300 Phase I clinical study to treat inflammatory diseases

Santarus commences SAN-300 Phase I clinical study to treat inflammatory diseases

Acorda reports fourth quarter net revenue of $133.1 million for full year ended December 31, 2010

Acorda reports fourth quarter net revenue of $133.1 million for full year ended December 31, 2010

Elan 2010 total revenue increases 5% to $1,169.7 million

Elan 2010 total revenue increases 5% to $1,169.7 million

Biogen Idec 2010 total revenues increase 8% to $4.7 billion

Biogen Idec 2010 total revenues increase 8% to $4.7 billion

Genentech, Biogen announce FDA approval of Rituxan to treat follicular lymphoma

Genentech, Biogen announce FDA approval of Rituxan to treat follicular lymphoma

EMA CHMP issues negative opinion against Biogen Idec's FAMPYRA for multiple sclerosis

EMA CHMP issues negative opinion against Biogen Idec's FAMPYRA for multiple sclerosis

Aegis releases Discoverant 4.0 manufacturing intelligence software

Aegis releases Discoverant 4.0 manufacturing intelligence software

Biogen Idec, Elan propose updated product labeling for TYSABRI to FDA and EMA

Biogen Idec, Elan propose updated product labeling for TYSABRI to FDA and EMA

Biogen Idec acquires Neurimmune subsidiary

Biogen Idec acquires Neurimmune subsidiary

Exciting progress made in MS research during 2010

Exciting progress made in MS research during 2010

Novartis' Gilenya uptake to increase

Novartis' Gilenya uptake to increase

Celebrity chef, registered dietitian team up to create nutrition program for people with MS

Celebrity chef, registered dietitian team up to create nutrition program for people with MS

EHSI negotiates potential option agreement with Regenetech for Rotary Cell Culture System

EHSI negotiates potential option agreement with Regenetech for Rotary Cell Culture System

First patient dosed with rFVIIIFc in A-LONG trial

First patient dosed with rFVIIIFc in A-LONG trial

Genentech, Biogen report Phase III study data of Rituxan in patients with advanced follicular lymphoma

Genentech, Biogen report Phase III study data of Rituxan in patients with advanced follicular lymphoma

New drug for non-Hodgkin’s lymphoma shows promise

New drug for non-Hodgkin’s lymphoma shows promise

AVEO's RON antibody shows anti-tumor activity in human cancer xenografts

AVEO's RON antibody shows anti-tumor activity in human cancer xenografts

Amorfix second quarter net loss decreases to $25,728

Amorfix second quarter net loss decreases to $25,728

BioWorld Today features ImmunGene's pipeline of next generation armed antibodies for cancer

BioWorld Today features ImmunGene's pipeline of next generation armed antibodies for cancer